Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature

Inflamm Bowel Dis. 2022 Mar 2;28(3):479-483. doi: 10.1093/ibd/izab212.

Authors

David Dulaney¹, Priya Dave², Samantha Walsh³, Saurabh Mehandru⁴, Jean-Frederic Colombel⁴, Manasi Agrawal⁴

Affiliations

¹ Department of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX, USA.
² Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Levy Library, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

No abstract available

Keywords: adverse event; anti-integrin; eosinophilic; inflammatory bowel disease; pulmonary; vedolizumab.

Publication types

Case Reports
Systematic Review

MeSH terms

Gastrointestinal Agents / therapeutic use
Humans
Inflammatory Bowel Diseases* / drug therapy
Integrins*

Substances

Gastrointestinal Agents
Integrins

Grants and funding

K23 DK129762/DK/NIDDK NIH HHS/United States